Interpace Diagnostics Group ( (IDXG) ) has shared an announcement.
Interpace Biosciences has announced an exchange of Series B Preferred Stock for Series C Preferred Stock with Ampersand Capital Partners and 1315 Capital, aiming to facilitate the uplisting of its Common Stock to Nasdaq. This move is expected to enhance investor interest and trading volume, while aligning with Interpace’s goal of raising growth capital. The Series C Preferred Stock, convertible into Common Stock, lacks certain rights of the Series B, which could streamline the company’s capital structure and potentially open new opportunities for growth in personalized medicine.
For a thorough assessment of IDXG stock, go to TipRanks’ Stock Analysis page.
